Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: ValuEngine, Inc.
$49.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sanofi SA Announces Results of New GetGoal-L Sub-analysis of Lyxumia


Tuesday, 24 Sep 2013 06:16am EDT 

Sanofi SA announced new GetGoal-L sub-analysis results showing that reductions in HbA1c with the Company's Lyxumia (lixisenatide), when added to basal insulin, were greatest in patients with type 2 diabetes who had well-controlled baseline fasting plasma glucose (FPG). These findings are consistent with the efficacy profile of Lyxumia, which shows a clinical and statistically reduction in HbA1c across different patient populations. 

Company Quote

82.29
0.3 +0.37%
5:08am EST